孤儿药
參考文獻

1 2 3 4 5  Armstrong, Walter. . Pharmaceutical Executive. May 2010.
1 2 3 4 5  Hadjivasiliou, Andreas,  (PDF), EvaluatePharma, October 2014  [28 June 2015], （原始内容存档 (PDF)于2015-10-10）
↑  Rich Daly (5 September 2002). "House Offers Incentives For Development of 'Orphan' Drugs". Congressional Quarterly Daily Monitor
↑  . US Food and Drug Administration. 20 December 2018  [28 December 2019]. （原始内容存档于2019-12-29）.
↑  Hall, Anthony K; Carlson, Marilyn R. . Intractable and Rare Diseases Research. 2014, 3 (1): 1–7. ISSN 2186-3644. PMC 4204542 . PMID 25343119. doi:10.5582/irdr.3.1.
1 2 3  Giannuzzi, Viviana; Conte, Rosa; Landi, Annalisa; Ottomano, Serena Antonella; Bonifazi, Donato; Baiardi, Paola; Bonifazi, Fedele; Ceci, Adriana. . Orphanet Journal of Rare Diseases. 3 April 2017, 12 (1): 64. ISSN 1750-1172. PMC 5376695 . PMID 28372595. doi:10.1186/s13023-017-0617-1.
1 2 3 4   (press release), New Delhi: Kuick Research, 7 Feb 2014  [20 March 2014], （原始内容存档于2021-11-23）
↑   (PDF). Thomson Reuters.   [28 July 2021]. （原始内容存档 (PDF)于2021-11-23）.
1 2 3  Laura Gaze, Jennifer Breen,  (PDF), Thomson Reuters, 2012  [29 June 2015], （原始内容 (PDF)存档于13 May 2015）
1 2 3  Meeking, Kiran N.; Williams, Cory S. M.; Arrowsmith, John E., , Drug Discovery Today, 15 August 2012, 17 (13–14): 660–664  [29 June 2015], PMID 22366309, doi:10.1016/j.drudis.2012.02.005, （原始内容存档于2022-01-29）
↑  . FDA.   [28 July 2021]. （原始内容存档于2022-01-19）.
↑  .   [2021-11-25]. （原始内容存档于2021-11-23）.
↑  .   [2021-11-25]. （原始内容存档于2022-01-28）.
↑  Shannon Gibson, Hamid R Raziee, and Trudo Lemmens. . World Medical & Health Policy. 19 March 2015, 7 (1): 3–27. PMC 4405057 . PMID 25914853. doi:10.1002/wmh3.131.
↑  Henkel, John. . FDA Consumer. U.S. Food and Drug Administration. 1999  [14 February 2009]. （原始内容存档于2008-10-05）.
1 2 3  Pollack, Andrew. . The New York Times. 30 April 1990  [15 February 2009]. （原始内容存档于2012-08-08）.
1 2  Illingworth, Patricia; Cohen, Jillian; Illingworth, P. . Health Law Journal. 2004, 12: 183–200. PMID 16539081.
↑  . Medterms.com. 2002-08-25  [2010-06-07]. （原始内容存档于2012-08-08）.
↑  Gerke, Sara; Pattinson, Shaun D.  (PDF). European Journal of Health Law. 2017-02-09, 24 (5): 541–564  [2021-11-25]. doi:10.1163/15718093-12341439. （原始内容存档 (PDF)于2019-04-27）.
↑  Donna Young. . BioWorld News (Washington). 2007-11-28  [2008-01-06]. In an attempt to simplify the process for obtaining orphan status for medications targeting rare diseases, the FDA and the European Medicines Agency (EMA) have created a common application. ... U.S. and European regulators still will conduct independent reviews of application submissions to ensure the data submitted meet the legal and scientific requirements of their respective jurisdictions, the agencies said.  Alt URL （页面存档备份，存于）
1 2 3 4  Andrew Duffy. . Windsor Star (Ontario). 23 February 2002.
↑  . 全國法規資料庫. 14 January 2015  [23 November 2021]. （原始内容存档于2021-11-23）.
↑  . 財團法人 罕見疾病基金會. 27 January 2018  [23 November 2021]. （原始内容存档于2021-11-23）. 我國依「罕見疾病及藥物審議委員會」的公告，則是以疾病盛行率萬分之一以下作為我國罕見疾病認定的標準。但罕病何其多，所以仍需經罕見疾病及藥物審議委員會認定，認定標準以罕見性〈萬分之一以下〉、治療困難性、遺傳性，三項指標來綜合認定。
↑  . CHEMISTRYWORLD. 30 August 2011  [29 July 2021]. （原始内容存档于2021-05-18）.
↑  .   [2021-11-25]. （原始内容存档于2021-11-23）.
↑  Denis, Alain; Mergaert, Lut; Fostier, Christel;  et al. . Applied Health Economics and Health Policy. 2010, 8 (5): 343–50. PMID 20804226. S2CID 27388954. doi:10.2165/11536990-000000000-00000.
↑  Arno, Peter S.; Bonuck, Karen; Davis, Michael. . The Milbank Quarterly. 1995-01-01, 73 (2): 231–252  [2021-11-25]. JSTOR 3350258. PMID 7776947. doi:10.2307/3350258. （原始内容存档于2019-04-28）.
↑  . Global Newswire. 2 November 2017  [2021-11-25]. （原始内容存档于2019-04-01）.
↑  Brooks, Megan. . fda.gov. US Federal Drug Administration. 10 August 2018  [5 May 2021]. （原始内容存档于2022-01-04） （英语）.
1 2  Wechsler, Jill. . Pharmaceutical Technology. July 2008.
↑  Hadjivasiliou, Andreas. . EvaulatePharma. 2015.
↑  Thomas, Katie. . The New York Times. 30 December 2016  [12 April 2017]. （原始内容存档于2020-11-08）.
↑  Schey, Carina; Milanova, Tsveta; Hutchings, Adam. . Orphanet Journal of Rare Diseases. 2011, 6 (62): 62. PMC 3191371 . PMID 21951518. doi:10.1186/1750-1172-6-62.
↑  Meekings, Kiran N.; Williams, Cory S. M.; Arrowsmith, John E. . Drug Discovery Today. 2012-07-01, 17 (13–14): 660–664. PMID 22366309. doi:10.1016/j.drudis.2012.02.005.
↑  Kesselheim, A. S.; Myers, J. A.; Avorn, J. . JAMA. 2011-06-08, 305 (22): 2320–2326. ISSN 0098-7484. PMID 21642684. doi:10.1001/jama.2011.769 .
↑  Crowe, Kelly, , CBC News, 25 June 2015  [25 June 2015], （原始内容存档于2015-06-26）
↑  .   [2021-11-25]. （原始内容存档于2021-09-14）.
↑  Drummond, M. F.; Grubert, N., , Spectrum Report, Decision Resources, Waltham, Mass., 2007
↑   (新闻稿). NICE. 20 April 2010  [15 Jun 2015]. （原始内容存档于2012-09-06）.
↑  . NICE. 2013  [15 Jun 2015]. （原始内容存档于7 May 2015）.
1 2  Drummond, Michael F. . Eurohealth. 2008, 14 (2): 16–257.
1 2  Drummond, Michael F; Wilson, David A. . International Journal of Technology Assessment in Health Care. 2007, 23 (1): 36–42. PMID 17234015. doi:10.1017/S0266462307051550.
1 2  McCabe, C; Claxton, K; Tsuchiya, A. . British Medical Journal. 2005, 331 (4): 1016–19. PMC 1273462 . PMID 16254305. doi:10.1136/bmj.331.7523.1016.
1 2  McCabe, C; Tsuchiya, A; Claxton, K; Raftery, J. . International Journal of Technology Assessment in Health Care. 2007, 23 (3): 397–404. PMID 17579945. doi:10.1017/s0266462307071012.
↑  Simoens, Steven. . Orphanet Journal of Rare Diseases. 2011-06-17, 6 (1): 42. PMC 3132155 . PMID 21682893. doi:10.1186/1750-1172-6-42 （英语）.
↑  . NICE.   [2021-03-29]. （原始内容存档于2021-11-23）.
↑   (新闻稿). NICE. 18 September 2014  [29 June 2015]. （原始内容存档于2022-01-20）.